AI Stock Analysis - Immunitybio (IBRX)
Analysis generated January 20, 2026.
Immunitybio is a biotechnology company focused on developing immunotherapies to treat various diseases, notably cancer. The company leverages its research and innovation capabilities to create products that can stimulate the immune system to fight off diseases. Immunitybio is involved in numerous clinical trials and has a robust pipeline of drugs awaiting approval.
Stock Alerts - Immunitybio (IBRX)
 |
Immunitybio | March 15 Reddit mentions are up by 151% in the last 24h. |
|
Immunitybio | March 14 Reddit mentions are up by 141% in the last 24h. |
|
Immunitybio | March 13 Price is up by 8.2% in the last 24h. |
|
Immunitybio | March 10 Price is down by -6.2% in the last 24h. |
Download our app to get future alerts delivered in real-time.
Alternative Data for Immunitybio
| Alternative Data | Value | 3m Change | Trend | Benchmark |
|---|---|---|---|---|
| Job Posts | 64 | Sign up | Sign up | Sign up |
| Sentiment | 60 | Sign up | Sign up | Sign up |
| Webpage traffic | 74,000 | Sign up | Sign up | Sign up |
| Employee Rating | 54 | Sign up | Sign up | Sign up |
| Google Trends | N/A | Sign up | Sign up | Sign up |
| 4chan Mentions | N/A | Sign up | Sign up | Sign up |
| Facebook Engagement | 65 | Sign up | Sign up | Sign up |
| Facebook Followers | 5,941 | Sign up | Sign up | Sign up |
| Reddit Mentions | 24 | Sign up | Sign up | Sign up |
| Stocktwits Mentions | 4,619 | Sign up | Sign up | Sign up |
| Stocktwits Subscribers | 27,840 | Sign up | Sign up | Sign up |
| X Followers | 18,687 | Sign up | Sign up | Sign up |
| X Mentions | 263 | Sign up | Sign up | Sign up |
| News Mentions | N/A | Sign up | Sign up | Sign up |
| Customer reviews | N/A | Sign up | Sign up | Sign up |
| Business Outlook | 33 | Sign up | Sign up | Sign up |
| Linkedin Employees | 610 | Sign up | Sign up | Sign up |
About Immunitybio
ImmunityBio, Inc., a clinical-stage biotechnology company, engages in developing therapies and vaccines that bolster the natural immune system to defeat cancers and infectious diseases.
| Price | $8.39 |
| Target Price | Sign up |
| Volume | 25,645,691 |
| Market Cap | $8.63B |
| Year Range | $1.98 - $11.55 |
| Dividend Yield | 0% |
| Analyst Rating | 50% buy |
| Industry | Biotechnology |
In the news
Piper Sandler Keeps an Overweight Rating on ImmunityBio, Inc. (IBRX)March 10 - Yahoo Entertainment |
|
 |
H.C. Wainwright Raised Its Price Target on ImmunityBio, Inc. (IBRX) to $15 from $10 and Maintains a Buy RatingMarch 6 - Yahoo Entertainment |
 |
ImmunityBio (IBRX) Shares Drop Nearly 10% as Investors Digest Recent EarningsMarch 4 - Ibtimes.com.au |
ImmunityBio, Inc. (IBRX) Price Target Raised After Strong ANKTIVA LaunchMarch 3 - Yahoo Entertainment |
|
ImmunityBio (IBRX) Reports 700% Revenue Surge Driven by Rapid ANKTIVA AdoptionFebruary 25 - Yahoo Entertainment |
|
ImmunityBio (IBRX) Skyrockets as Anktiva Propels 671% Revenue JumpFebruary 24 - Yahoo Entertainment |
|
Financial performance View All
| Revenue | Cost of Revenue | Gross Profit | Net Income | ebitda | EPS | |
|---|---|---|---|---|---|---|
| Q3 '25 | 32M | 4.1M | 28M | -67M | -36M | -0.070 |
| Q2 '25 | 26M | 140,000 | 26M | -93M | -60M | -0.100 |
| Q1 '25 | 17M | 58,000 | 16M | -130M | -97M | -0.150 |
| Q4 '24 | 7.6M | 4.1M | 7.6M | -59M | -40M | -0.080 |
| Q3 '24 | 6.1M | 150,000 | 6.1M | -86M | -41M | -0.123 |
Insider Transactions View All
| Simon Barry J. filed to sell 2,850,821 shares at $12. February 26 '26 |
| Simon Barry J. filed to sell 2,925,821 shares at $10.2. February 24 '26 |
| Simon Barry J. filed to sell 3,081,604 shares at $9.3. February 24 '26 |
| Simon Barry J. filed to sell 3,091,604 shares at $7.9. January 21 '26 |
Similar companies
Read more about Immunitybio (IBRX) and their ai stock analysis, price prediction, earnings, congress trading, insider transactions, technical analysis, job posts, sentiment, webpage traffic, employee rating, google trends, 4chan mentions, facebook engagement, facebook followers, reddit mentions, stocktwits mentions, stocktwits subscribers, x followers, x mentions, news mentions, customer reviews, business outlook & linkedin employees.
FAQ - Immunitybio
The Market Cap of Immunitybio is $8.63B.
Currently, the price of one share of Immunitybio stock is $8.39.
The IBRX stock price chart above provides a comprehensive visual representation of Immunitybio's stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling Immunitybio shares. Our platform offers an up-to-date IBRX stock price chart, along with technical data analysis and alternative data insights.
As of our latest update, Immunitybio (IBRX) does not offer dividends to its shareholders. Investors interested in Immunitybio should consider the potential for capital appreciation as the primary return on investment, rather than expecting dividend payouts.
Some of the similar stocks of Immunitybio are Amgen, Gilead Sciences, Catalyst Pharmaceuticals, Inovio Pharmaceuticals, and Anavex Life Sciences.
